Health Trials

About this trial

This study aims to explore the potential of RDN as a therapy for HFpEF in a Prospective, Multicenter, Randomized, Blinded, Sham-controlled Study.

Eligibility criteria

Qualifiers

signs or symptoms of heart failure;

normal or mildly abnormal systolic LV function (LVEF ≥ 50%);

evidence of diastolic LV dysfunction.

Individual should fulfill the diagnostic WHO criteria for hypertension: SBP > 140 mmHg and/or DBP > 90 mmHg, and is treated with at least 2 antihypertensive drugs. This treatment is expected to be maintained for at least 6 months. Using this regimen the blood pressure should be adequately controlled (< 140/90mmHg by 24 hour ambulatory BP measurement).

Disqualifiers

Known secondary cause of hypertension

Anatomy not eligible for renal denervation

Systolic heart failure (LVEF < 50%)

Individual has an estimated glomerular filtration rate (eGFR) of < 30mL/min/1.73m2, using the MDRD calculation.

Trial design

Treatments tested in this trial

  • Sham procedure and maintenance of heart failure medications
  • Renal denervation and maintenance of heart failure medications

Treatment groups

200 Participants
are divided into 2 treatment groups

Locations

1
The First Affiliated Hospital of Xinjiang Medical University830000, ÜrümqiXinjiang, China

Sponsors and collaborators

Xinjiang Medical University

Lead sponsor

First Affiliated Hospital of Xinjiang Medical University

Sponsor institution

First Affiliated Hospital of Xinjiang Medical University

Collaborator

Source ClinicalTrials.gov